Picture of Divi's Laboratories logo

DIVISLAB — Divi's Laboratories News Story

0.000.00%
in flag iconLast trade - 00:00
HealthcareConservativeLarge CapHigh Flyer

India's Divi's Labs up 3% on upbeat analysts' views

** Shares of Divi's Laboratories  DIVI.NS  rise as much as
3.2% to 3,198 rupees, biggest pct gain since May 9
    ** Brokerage firm Jefferies upgrades DIVI to "buy" from
"underperform;" PT raised to 3,610 rupees from 2,550 rupees
    ** Q4 Revenue/EBITDA declined 23%/56% YoY but was ahead of
estimates - Jefferies 
    ** Adds, co should be back to achieving mid/high teens
revenue growth from Q2FY24 with EBITDA growing at a faster pace
due to leverage benefits and softening input costs
    ** Besides, brokerage raises FY24/25 EPS estimates by 4-13%
    ** Analysts at Motilal Oswal, too, raise DIVI's earnings
estimates for FY24/FY25 by 7%/6% 
    ** More than 764,000 shares change hands by 11:20 a.m. IST,
1.2x 30-day avg of 614,371 shares
    ** Four of the 22 analysts covering the stock have a "buy"
or "strong buy" rating, 10 "hold," while 8 rate it "sell" or
"strong sell;" median PT is 2,865 rupees - Refinitiv IBES data


 (Reporting by Ashna Teresa Britto in Bengaluru)
 ((AshnaTeresa.Britto@thomsonreuters.com ; ( +91 8078332441))

Recent news on Divi's Laboratories

See all news